Clinical Trial Search

Primary: Change-from-baseline QT Interval Corrected for Heart Rate Using Fridericia's Method (QTcF) — 1.5; 0.9 msec

Primary: Number of Participants With Adverse Events (AEs) — 0; 0; 1; 1 Participants

Primary: Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event (TEAE) — 50.0; 33.3; 83.3; 16.7 Percentage of participants

Primary: Number of Patients Who Had an Adverse Events — 25 Participants

Primary: Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 3 — 11.5 meters

Primary: Nefopam and Paracetamol Pharmacokinetic Profiles in Each Arms After Single Dose — 101.808; 114.957; NA; 118.528 ng/mL

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0 Participants

Primary: Part 1: Percentage of Participants With Adverse Events — 27.3; 33.3; 50.0; 100 Percentage of participants

Primary: Cohort 1 and Cohort 4: Percentage of Participants With Objective Response (OR) as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors…

Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib — 21600; 19100; 21000…

Primary: Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets — -10.31; 5.12; -16.39; -26.76 Percent Change

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) During Dose Escalation Phase — 0; 1; 0; 0 Participants

Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter

Primary: Change From Baseline in Averaged Correct Response Rate on the One Card Learning Task to Week 8 — 0.055; 0.034 Proportion of correct response

Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 6 Participants